Linehan Lab ManagerUniversity of Rochester, United States
43: An Update On The Phase I Study to Evaluate the Safety and Tolerability of SX-682 in Combination with Anti-PD1 as Maintenance Therapy for Unresectable Pancreatic Adenocarcinoma
Thursday, March 21, 20242:12pm – 2:22pm ET